Please login to the form below
lung disease
This page shows the latest lung disease news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Amgen’s Lumykras for non-small-cell lung cancer
It will be available as an option for adult patients diagnosed with the KRAS G12C mutation-positive locally advanced, or metastatic non-small-cell lung cancer (NSCLC) patients, whose disease has ... lung cancers and approximately 13% of these are
Latest news
-
Roche's lung cancer combination treatment improves long-term survival
line PD-L1-positive, locally advanced unresectable or metastatic non-small cell lung cancer. ... plus Tecentriq in early and metastatic disease in both lung and oesophageal cancers.
-
FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
All participants in this trial had at least one risk factor for developing severe COVID-19, including chronic lung disease, obesity, cardiovascular disease or were at least 50 years of age. ... high-risk of severe disease or hospitalisation.
-
Mysterious big pharma company eyes US biotech Acceleron
In pulmonology, Acceleron also has an early-stage candidate, ACE-1334, that is expected to move into phase 1b/phase 2, focused on systemic sclerosis-associated interstitial lung disease (SSc-ILD) ... The FDA has awarded sotatercept breakthrough
-
Detailed results for Regeneron's antibody cocktail continue to show benefit in high-risk COVID-19 outpatients
All participants in this trial had at least one risk factor for developing severe COVID-19, including chronic lung disease, obesity, cardiovascular disease or were at least 50 years of age. ... In the US, REGEN-COV is authorised for emergency use to
-
AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial
palivizumab) among preterm infants and children with chronic lung disease (CLD) and congenital heart disease (CHD).
More from news
Approximately 4 fully matching, plus 124 partially matching documents found.
Latest Intelligence
-
Addressing the payer-regulator evidence gap in early-stage cancer
complications of disease whether measured symptomatically, radiographically, and increasingly with novel measurement techniques. ... endpoints that can better characterise the benefit of new drugs for early disease.
-
GSK forges ahead with its dynamic COPD and asthma portfolio
The lexicon of lung disease has been developing over four centuries from its early livid descriptions such as turgid, voluminous and catarrh coined by physicians navigating various airflow restrictions now known ... COPD was a Cinderella disease when I
-
#OrkambiNow?
People with this genetically inherited disease are vulnerable to potentially deadly lung infections, and currently half the people in the UK with CF die before the age of 31. ... died from the disease who might have lived had they received the drug.
-
Significant figures
ALIS (Amikacin liposome inhalation suspension) is being developed as a treatment for refractory non tuberculous Mycobacterial (NTM) lung disease, a rare progressive, destructive infection caused by mycobacterium avium complex. ... However, Insmed
-
Pharma deals during August 2014
lung scarring condition for which there are no approved drugs in the US. ... It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease.
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest appointments
-
V Bryan Lawlis joins board of KaloBios
This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Can tobacco companies really reinvent themselves as healthcare companies?
But can tobacco companies reinvent themselves as healthcare companies? Since smoking was linked to serious diseases such as lung cancer in the 1950s, health experts have been focused on influencing consumer ... Vectura has also been highly criticised for
-
October 2020: diversity and inclusion in clinical trials round-up
People with chronic conditions such as diabetes, lung disease, and heart disease, and those of advanced age, had a poorer prognosis once infected with COVID-19. ... In such settings, specialised sickle cell disease services and treatment is often
-
It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016
The judges recognised our use of digital and film as mechanisms to help bring lung cancer, a disease that has one of the lowest survival rates of any cancer, to the ... preventing this disease, which is responsible for the deaths of more people in the UK
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- My journey advancing the science in pulmonary hypertension
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- A creative awakening – how pharma is bringing innovation to the patient journey
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Shionogi Europe and NHS England agree on antibiotic subscription model
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
